Cargando…
Ensuring care for clozapine-treated schizophrenia patients during the COVID-19 pandemic
Autores principales: | Nichols, Jessica, Gannon, Jessica M., Conlogue, Judith, Sarpal, Deepak, Montgomery, Jamie L., Sherwood, Robin, Fabian, Tanya, Ballough, Juliette R., Fredrick, Noreen M., Chengappa, K.N. Roy |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247984/ https://www.ncbi.nlm.nih.gov/pubmed/32473934 http://dx.doi.org/10.1016/j.schres.2020.05.053 |
Ejemplares similares
-
Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions
por: Gannon, Jessica M., et al.
Publicado: (2020) -
Changes in corticostriatal connectivity and striatal tissue iron associated with efficacy of clozapine for treatment‑resistant schizophrenia
por: Blazer, Annie, et al.
Publicado: (2022) -
COVID-19 infection, fluctuations in the clozapine/norclozapine levels and metabolic ratio and clozapine toxicity: An illustrative case-report
por: Chengappa, K.N. Roy, et al.
Publicado: (2022) -
Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
por: Montgomery, Adam, et al.
Publicado: (2023) -
Management of patients with Clozapine Resistant Schizophrenia
por: Rajendran*, Nithya Ragavi, et al.
Publicado: (2022)